Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GWPCARE5: Cannabidiol OLE in Dravet or Lennox-Gastaut Syndromes
NCT02224573Phase 3Completed
- Sponsor
- GW Pharmaceuticals
- Start
- Jun 2015
- Primary completion
- Sep 2020
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of cannabidiol in Dravet syndrome, Lennox-Gastaut syndrome (LGS), sponsored by GW Pharmaceuticals. Started Jun 2015; status: completed.
02
Drugs
cannabidiol
03
Conditions
Dravet syndromeLennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on NCT02224573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02224573.